4//SEC Filing
Dybbs Michael 4
Accession 0001209191-17-059625
CIK 0001592288other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 5:06 PM ET
Size
9.1 KB
Accession
0001209191-17-059625
Insider Transaction Report
Form 4
Dybbs Michael
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2017-11-07−32,069→ 0 totalExercise: $7.08Exp: 2026-05-18→ Common Stock (32,069 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2017-11-07−17,000→ 0 totalExercise: $1.15Exp: 2027-05-24→ Common Stock (17,000 underlying)
Footnotes (2)
- [F1]These options were assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
- [F2]These options, which vest in full on the earlier of May 25, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board, were assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Documents
Issuer
Dimension Therapeutics, Inc.
CIK 0001592288
Entity typeother
Related Parties
1- filerCIK 0001601264
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 5:06 PM ET
- Size
- 9.1 KB